April Dovholuk

April Dovholuk has a comprehensive background in clinical operations and drug development. April has held various leadership roles within the pharmaceutical industry.

April began their career at Curis as an Associate in Clinical Research and Manufacturing in 2001. April then moved on to Antigenics, where they worked as a Senior Clinical Research Associate, Clinical Project Associate, and Clinical Trial Associate from 2004 to 2005. April joined ArQule as a Clinical Project Manager, specializing in oncology clinical research and clinical development from 2005 to 2007.

In 2007, April joined Idera Pharmaceuticals as an Associate Director of Clinical, where they worked on Mergers & Acquisitions (M&A) and regulatory filings. April also gained exposure to new indications outside of oncology, such as Hepatitis C.

April's next venture was at Takeda Oncology, where they had progressive roles from Associate Director of Clinical Operations to Senior Director of Clinical Operations, leading clinical trials, CRO management, and regulatory approvals. April managed a late-stage oncology portfolio with numerous assets and clinical trials, and successfully accelerated the portfolio.

April then transitioned to Replimune as a VP and later SVP of Global Development Operations. Here, they guided a team of drug development professionals, oversaw multiple assets and clinical trials, and actively contributed to corporate goals. April was responsible for clinical operations, data management, outsourcing, contract management, budgeting, and process improvement.

Currently, April is an SVP of Development Operations at Centessa Pharmaceuticals, a role they assumed in 2023.

Throughout their career, April has consistently demonstrated strong leadership, strategic thinking, and the ability to drive results.

April Dovholuk obtained a Bachelor's degree in Science from Cornell University, where they studied from 1996 to 2000.